{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:38:46Z","timestamp":1710549526523},"posted":{"date-parts":[[2024,3,15]]},"group-title":"In Review","reference-count":56,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Background\n To interrupt residual malaria transmission and achieve successful elimination of <jats:italic>P. falciparum<\/jats:italic> in low-transmission settings, the World Health Organization (WHO) recommends the administration of a single dose of 0.25 mg\/kg (or 15 mg\/kg for adults) primaquine (PQ) combined with artemisinin-based combination therapy (ACT) without glucose-6-phosphate dehydrogenase (G6PD) testing. However, due to the risk of hemolysis in patients with G6PD deficiency (G6PDd), PQ use is not as common. Thus, this study aimed to assess the safety of a single low dose of PQ administered to patients with G6PD deficiency.\nMethods\n An observational cohort study was conducted with patients treated for uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria with either single-dose PQ (0.25 mg\/kg) (SLD PQ)\u2009+\u2009ACT or ACT alone. Microscopy-confirmed uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria patients visiting public health facilities in Arjo Didessa, Southwest Ethiopia, were enrolled in the study from September 2019 to November 2022. Patients with uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria were followed up for 28 days through clinical and laboratory diagnosis, such as measurements of G6PD levels and hemoglobin (Hb) concentrations. G6PD levels were masured by a quantiative biosensor machine. Patient interviews were also conducted, and the type and frequency of clinical complaints were recorded. Hb data were taken on days (D) 7, 14, 21, and 28 following treatment with SLD-PQ\u2009+\u2009ACT or ACT alone.\nResults\n A total of 249 patients with uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria were enrolled in this study. Of these, 83 (33.3%) patients received ACT alone, and 166 (66.7%) received ACT combined with SLD-PQ treatment. The median age of the patients was 20 (IQR 14) years. G6PD deficiency was found in 17 (6.8%) patients, 14 males and 3 females. There were 6 (7.2%) and 11 (6.6%) phenotypic G6PD-deficient patients in the ACT alone and ACT\u2009+\u2009SLD-PQ arms, respectively. The mean Hb levels in patients treated with ACT\u2009+\u2009SLD-PQ were reduced by an average of 0.45 g\/dl (95% CI\u2009=\u20090.39 to 0.52) in the posttreatment phase (D7) compared to a reduction of 0.30 g\/dl (95% CI\u2009=\u20090.14 to -0.47) in patients treated with ACT alone (<jats:italic>P<\/jats:italic>\u2009=\u20090.157). A greater mean Hb reduction was observed on day 7 in the G6PD deficiency group (-0.56 g\/dL) than in the G6PD normal group (-0.39 g\/dL); however, there was no statistically significant difference (<jats:italic>P<\/jats:italic>\u2009=\u20090.359). Overall, D14 losses were 0.10 g\/dl (95% CI = -0.00 to 0.20) and 0.05 g\/dl (95% CI = -0.123 to 0.22) in patients with and without SLD-PQ, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.412).\nConclusions\n Our findings showed that single low-dose primaquine (SLD-PQ) treatment for uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria is safe and does not increase the risk of hemolysis in G6PDd patients. This evidence suggests that the wider deployment of SLD-PQ for <jats:italic>P. falciparum<\/jats:italic> is part of a global strategy for eliminating <jats:italic>P. falciparum<\/jats:italic> malaria.<\/jats:p>","DOI":"10.21203\/rs.3.rs-4095915\/v1","type":"posted-content","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:39:37Z","timestamp":1710527977000},"source":"Crossref","is-referenced-by-count":0,"title":["The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on hemoglobin levels in Ethiopia: a longitudinal cohort study"],"prefix":"10.21203","author":[{"given":"Kassahun","family":"Habtamu","sequence":"first","affiliation":[{"name":"Addis Ababa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hallelujah","family":"Getachew","sequence":"additional","affiliation":[{"name":"Arbaminch College of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashenafi","family":"Abossie","sequence":"additional","affiliation":[{"name":"Arba Minch University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assalif","family":"Demissew","sequence":"additional","affiliation":[{"name":"Ambo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arega","family":"Tsegaye","sequence":"additional","affiliation":[{"name":"Jimma University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teshome","family":"Degefa","sequence":"additional","affiliation":[{"name":"Jimma University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[{"name":"University of California at Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chieh","family":"Lee","sequence":"additional","affiliation":[{"name":"University of California at Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofa","family":"Zhou","sequence":"additional","affiliation":[{"name":"University of California at Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Kibret","sequence":"additional","affiliation":[{"name":"West Valley Mosquito and Vector Control District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[{"name":"Case Western Reserve University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Kazura","sequence":"additional","affiliation":[{"name":"Jimma University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beyene","family":"Petros","sequence":"additional","affiliation":[{"name":"Addis Ababa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delenasaw","family":"Yewhalaw","sequence":"additional","affiliation":[{"name":"Jimma University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiyun","family":"Yan","sequence":"additional","affiliation":[{"name":"University of California at Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12936-016-1408-1","article-title":"Impact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zone","volume":"15","author":"Pousibet-Puerto J","year":"2016","unstructured":"Pousibet-Puerto J, Salas-Coronas J, S\u00e1nchez-Crespo A, Molina-Arrebola MA, Soriano-P\u00e9rez MJ, Gim\u00e9nez-L\u00f3pez MJ, V\u00e1zquez-Villegas J, Cabezas-Fern\u00e1ndez MT. Impact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zone. Malar J. 2016;15:339.","journal-title":"Malar J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","article-title":"Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data","volume":"14","author":"Group WGS","year":"2016","unstructured":"Group WGS. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Med. 2016;14:79.","journal-title":"BMC Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","article-title":"Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Gon\u00e7alves BP","year":"2016","unstructured":"Gon\u00e7alves BP, Tiono AB, Ou\u00e9draogo A, Guelb\u00e9ogo WM, Bradley J, Nebie I, Siaka D, Lanke K, Eziefula AC, Diarra A, et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:40.","journal-title":"BMC Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12936-018-2373-7","article-title":"Plasmodium falciparum gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment","volume":"17","author":"Roth JM","year":"2018","unstructured":"Roth JM, Sawa P, Omweri G, Osoti V, Makio N, Bradley J, Bousema T, Schallig H, Mens PF. Plasmodium falciparum gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment. Malar J. 2018;17:223.","journal-title":"Malar J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/parasitologia2020011","article-title":"Antimalarial Drug Strategies to Target Plasmodium Gametocytes","volume":"2","author":"Munro BA","year":"2022","unstructured":"Munro BA, McMorran BJ. Antimalarial Drug Strategies to Target Plasmodium Gametocytes. Parasitologia. 2022;2:101\u201324.","journal-title":"Parasitologia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/cix355","article-title":"Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial","volume":"65","author":"Tine RC","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, Wang D, Ndiaye M, Ndiaye JL, Faye B. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clin Infect Dis. 2017;65:535\u201343.","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2666-5247(21)00192-0","article-title":"Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: a four-arm, single-blind, phase 2\/3, randomized trial","volume":"3","author":"Stone W","year":"2022","unstructured":"Stone W, Mahamar A, Sanogo K, Sinaba Y, Niambele SM, Sacko A, Keita S, Youssouf A, Diallo M, Soumare HM. Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: a four-arm, single-blind, phase 2\/3, randomized trial. Lancet Microbe. 2022;3:e41\u201351.","journal-title":"Lancet Microbe"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-017-0990-6","article-title":"Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria\u2013a proposed model-derived age-based regimen for sub-Saharan Africa","volume":"16","author":"Taylor WR","year":"2018","unstructured":"Taylor WR, Naw HK, Maitland K, Williams TN, Kapulu M, D\u2019Alessandro U, Berkley JA, Bejon P, Okebe J, Achan J. Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria\u2013a proposed model-derived age-based regimen for sub-Saharan Africa. BMC Med. 2018;16:1\u201314.","journal-title":"BMC Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e0168702","DOI":"10.1371\/journal.pone.0168702","article-title":"Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: an open-label randomized trial","volume":"12","author":"Lin JT","year":"2017","unstructured":"Lin JT, Lon C, Spring MD, Sok S, Chann S, Ittiverakul M, Kuntawunginn W, My M, Thay K, Rahman R. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: an open-label randomized trial. PLoS ONE. 2017;12:e0168702.","journal-title":"PLoS ONE"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-022-00185-3","article-title":"Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication","volume":"8","author":"Habtamu K","year":"2022","unstructured":"Habtamu K, Petros B, Yan G. Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication. Trop Dis Travel Med Vaccines. 2022;8:1\u201317.","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"ref11","volume-title":"WHO Guidelines for Malaria, 16 February 2021","author":"WHO","year":"2021","unstructured":"WHO. WHO Guidelines for Malaria, 16 February 2021. World Health Organization Geneva, Switzerland; 2021."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e0006230","DOI":"10.1371\/journal.pntd.0006230","article-title":"Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries","volume":"12","author":"Recht J","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12:e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12936-018-2248-y","article-title":"Primaquine-induced hemolysis in females heterozygous for G6PD deficiency","volume":"17","author":"Chu CS","year":"2018","unstructured":"Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced hemolysis in females heterozygous for G6PD deficiency. Malar J. 2018;17:101.","journal-title":"Malar J"},{"key":"ref14","author":"Kawulur HS","year":"2020","unstructured":"Kawulur HS, Krismawati H, Imaniar C. Screening of glucose-6-phosphate dehydrogenase (G6PD) deficiency in two high endemic malaria populations, West Papua province and North Moluccas. In AIP Conference ProceedingsAIP Publishing; 2020."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"17106","DOI":"10.1038\/s41598-020-74200-y","article-title":"Glucose-6-phosphate dehydrogenase deficiency in the Han Chinese population: molecular characterization and genotype\u2013phenotype association throughout an activity distribution","volume":"10","author":"He Y","year":"2020","unstructured":"He Y, Zhang Y, Chen X, Wang Q, Ling L, Xu Y. Glucose-6-phosphate dehydrogenase deficiency in the Han Chinese population: molecular characterization and genotype\u2013phenotype association throughout an activity distribution. Sci Rep. 2020;10:17106.","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12936-018-2271-z","article-title":"Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a preelimination setting in southern Africa","volume":"17","author":"Awandu SS","year":"2018","unstructured":"Awandu SS, Raman J, Makhanthisa TI, Kruger P, Frean J, Bousema T, Niemand J, Birkholtz L-M. Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a preelimination setting in southern Africa. Malar J. 2018;17:120.","journal-title":"Malar J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","article-title":"Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial","volume":"18","author":"Raman J","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, Frean J, Wiesner L, Barnes KI. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"ref18","first-page":"1","article-title":"Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania","volume":"15","author":"Mwaiswelo R","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, Mmbando BP, Bj\u00f6rkman A, M\u00e5rtensson A. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:1\u201311.","journal-title":"Malar J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-022-04100-1","article-title":"A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania","volume":"21","author":"Mwaiswelo RO","year":"2022","unstructured":"Mwaiswelo RO, Ngasala B, Msolo D, Kweka E, Mmbando BP, M\u00e5rtensson A. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania. Malar J. 2022;21:1\u201315.","journal-title":"Malar J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/cix355","article-title":"Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial","volume":"65","author":"Tine RC","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, Wang D, Ndiaye M, Ndiaye JL, Faye B, et al. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. Clin Infect Dis. 2017;65:535\u201343.","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-016-1410-7","article-title":"Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study","volume":"15","author":"Poirot E","year":"2016","unstructured":"Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, Vilakati S, Pan S, Darteh S, Maphalala G. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016;15:1\u201312.","journal-title":"Malar J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e0190272","DOI":"10.1371\/journal.pone.0190272","article-title":"Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials","volume":"13","author":"Bastiaens GJ","year":"2018","unstructured":"Bastiaens GJ, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Goncalves BP, Affara M, Ouedraogo A, Bougouma EC, Sanou GS. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials. PLoS ONE. 2018;13:e0190272.","journal-title":"PLoS ONE"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1473-3099(22)00658-2","article-title":"Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"23","author":"Taylor WR","year":"2023","unstructured":"Taylor WR, Olupot-Olupot P, Onyamboko MA, Peerawaranun P, Weere W, Namayanja C, Onyas P, Titin H, Baseke J, Muhindo R. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomized, double-blind, placebo-controlled, noninferiority trial. Lancet Infect Dis. 2023;23:471\u201383.","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiy014","article-title":"Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial","volume":"217","author":"Chen I","year":"2018","unstructured":"Chen I, Diawara H, Mahamar A, Sanogo K, Keita S, Kone D, Diarra K, Djimde M, Keita M, Brown J, et al. Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial. J Infect Dis. 2018;217:1298\u2013308.","journal-title":"J Infect Dis"},{"key":"ref25","first-page":"1","article-title":"Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa","volume":"14","author":"Beek SW","year":"2021","unstructured":"van Beek SW, Svensson EM, Tiono AB, Okebe J, D\u2019Alessandro U, Gon\u00e7alves BP, Bousema T, Drakeley C, Ter Heine R. Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa. Parasites vectors. 2021;14:1\u201311.","journal-title":"Parasites vectors"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e1023","DOI":"10.1371\/journal.pone.0001023","article-title":"Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate","volume":"2","author":"Shekalaghe S","year":"2007","unstructured":"Shekalaghe S, Drakeley C, Gosling R, Ndaro A, Van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS ONE. 2007;2:e1023.","journal-title":"PLoS ONE"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12916-022-02504-z","article-title":"Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data","volume":"20","author":"Stepniewska K","year":"2022","unstructured":"Stepniewska K, Allen EN, Humphreys GS, Poirot E, Craig E, Kennon K, Yilma D, Bousema T, Guerin PJ, White NJ, et al. Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. BMC Med. 2022;20:350.","journal-title":"BMC Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12916-022-02504-z","article-title":"Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data","volume":"20","author":"Stepniewska K","year":"2022","unstructured":"Stepniewska K, Allen EN, Humphreys GS, Poirot E, Craig E, Kennon K, Yilma D, Bousema T, Guerin PJ, White NJ. Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. BMC Med. 2022;20:350.","journal-title":"BMC Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"104805","DOI":"10.1016\/j.ebiom.2023.104805","article-title":"Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria","volume":"96","author":"Mukaka M","year":"2023","unstructured":"Mukaka M, Onyamboko MA, Olupot-Olupot P, Peerawaranun P, Suwannasin K, Pagornrat W, Kouhathong J, Madmanee W, Were W, Namayanja C, et al. Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria. eBioMedicine. 2023;96:104805.","journal-title":"eBioMedicine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/cix355","article-title":"Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial","volume":"65","author":"Tine RC","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, Wang D, Ndiaye M, Ndiaye JL, Faye B, et al. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. Clin Infect Dis. 2017;65:535\u201343.","journal-title":"Clin Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","article-title":"Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomized controlled trial","volume":"18","author":"Dicko A","year":"2018","unstructured":"Dicko A, Roh ME, Diawara H, Mahamar A, Soumare HM, Lanke K, Bradley J, Sanogo K, Kone DT, Diarra K, et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomized controlled trial. Lancet Infect Dis. 2018;18:627\u201339.","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12936-020-03416-0","article-title":"Impact of sugarcane irrigation on malaria vector Anopheles mosquito fauna, abundance and seasonality in Arjo-Didessa, Ethiopia","volume":"19","author":"Demissew A","year":"2020","unstructured":"Demissew A, Hawaria D, Kibret S, Animut A, Tsegaye A, Lee MC, Yan G, Yewhalaw D. Impact of sugarcane irrigation on malaria vector Anopheles mosquito fauna, abundance and seasonality in Arjo-Didessa, Ethiopia. Malar J. 2020;19:344.","journal-title":"Malar J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12936-023-04782-1","article-title":"Anopheles larval habitats seasonality and environmental factors affecting larval abundance and distribution in Arjo-Didessa sugarcane plantation, Ethiopia","volume":"22","author":"Tsegaye A","year":"2023","unstructured":"Tsegaye A, Demissew A, Hawaria D, Abossie A, Getachew H, Habtamu K, Degefa T, Wang X, Lee M-C, Zhou G, et al. Anopheles larval habitats seasonality and environmental factors affecting larval abundance and distribution in Arjo-Didessa sugarcane plantation, Ethiopia. Malar J. 2023;22:350.","journal-title":"Malar J"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12936-023-04762-5","article-title":"Asymptomatic and submicroscopic malaria infections in sugarcane and rice development areas of Ethiopia","volume":"22","author":"Getachew H","year":"2023","unstructured":"Getachew H, Demissew A, Abossie A, Habtamu K, Wang X, Zhong D, Zhou G, Lee M-C, Hemming-Schroeder E, Bradley L, et al. Asymptomatic and submicroscopic malaria infections in sugarcane and rice development areas of Ethiopia. Malar J. 2023;22:341.","journal-title":"Malar J"},{"key":"ref35","unstructured":"WHO: Methods for surveillance of antimalarial drug efficacy. 2009. 2015."},{"key":"ref36","volume-title":"WHO guidelines for malaria, 14 March 2023","author":"WHO","year":"2023","unstructured":"WHO. WHO guidelines for malaria, 14 March 2023. World Health Organization; 2023."},{"key":"ref37","author":"Ababa A","year":"2018","unstructured":"Ababa A. National malaria guidelines. 2018."},{"key":"ref38","unstructured":"FMoH. National malaria guidelines. 2018."},{"key":"ref39","volume-title":"Giemsa staining of malaria blood films","author":"Organization WH","year":"2016","unstructured":"Organization WH. Giemsa staining of malaria blood films. World Health Organization; 2016."},{"key":"ref40","volume-title":"Basic malaria microscopy","author":"WHO","year":"2010","unstructured":"WHO. Basic malaria microscopy. World Health Organization; 2010."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1038\/s41598-021-82477-w","article-title":"Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Lue ethnic group of northern Thailand","volume":"11","author":"Sathupak S","year":"2021","unstructured":"Sathupak S, Leecharoenkiat K, Kampuansai J. Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Lue ethnic group of northern Thailand. Sci Rep. 2021;11:2956.","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12936-022-04269-5","article-title":"Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health center, Eastern Ethiopia","volume":"21","author":"Shenkutie TT","year":"2022","unstructured":"Shenkutie TT, Nega D, Hailu A, Kepple D, Witherspoon L, Lo E, Negash MT, Adamu A, Gebremichael SG, Gidey B. Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health center, Eastern Ethiopia. Malar J. 2022;21:260.","journal-title":"Malar J"},{"key":"ref43","first-page":"1","article-title":"Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia","volume":"18","author":"Lo E","year":"2019","unstructured":"Lo E, Zhong D, Raya B, Pestana K, Koepfli C, Lee M-C, Yewhalaw D, Yan G. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. Malar J. 2019;18:1\u201310.","journal-title":"Malar J"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/diagnostics13243647","article-title":"Preliminary Investigation into the Prevalence of G6PD Deficiency in a Pediatric African American Population Using a Near-Patient Diagnostic Platform","volume":"13","author":"Leung-Pineda V","year":"2023","unstructured":"Leung-Pineda V, Weinzierl EP, Rogers BB. Preliminary Investigation into the Prevalence of G6PD Deficiency in a Pediatric African American Population Using a Near-Patient Diagnostic Platform. Diagnostics. 2023;13:3647.","journal-title":"Diagnostics"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/inthealth\/ihy060","article-title":"Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities","volume":"11","author":"Domingo GJ","year":"2019","unstructured":"Domingo GJ, Advani N, Satyagraha AW, Sibley CH, Rowley E, Kalnoky M, Cohen J, Parker M, Kelley M. Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. Int health. 2019;11:7\u201314.","journal-title":"Int health"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(23)01553-2","article-title":"Primaquine radical cure in patients with Plasmodium falciparum malaria in areas coendemic for P falciparum and Plasmodium vivax (PRIMA): a multicenter, open-label, superiority randomized controlled trial","volume":"402","author":"Thriemer K","year":"2023","unstructured":"Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, Hossain MS, Kibria MG, Tego TT, Abate DT, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas coendemic for P falciparum and Plasmodium vivax (PRIMA): a multicenter, open-label, superiority randomized controlled trial. Lancet. 2023;402:2101\u201310.","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12936-020-3121-3","article-title":"Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when coadministered with artemether\u2013lumefantrine","volume":"19","author":"Shekalaghe S","year":"2020","unstructured":"Shekalaghe S, Mosha D, Hamad A, Mbaga TA, Mihayo M, Bousema T, Drakeley C, Abdulla S. Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when coadministered with artemether\u2013lumefantrine. Malar J. 2020;19:34.","journal-title":"Malar J"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiy014","article-title":"Safety of single-dose primaquine in G6PD-deficient and G6PD-normal males in Mali without malaria: an open-label, phase 1, dose-adjustment trial","volume":"217","author":"Chen I","year":"2018","unstructured":"Chen I, Diawara H, Mahamar A, Sanogo K, Keita S, Kone D, Diarra K, Djimde M, Keita M, Brown J. Safety of single-dose primaquine in G6PD-deficient and G6PD-normal males in Mali without malaria: an open-label, phase 1, dose-adjustment trial. J Infect Dis. 2018;217:1298\u2013308.","journal-title":"J Infect Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-018-2564-2","article-title":"G6PD deficiency, primaquine treatment, and risk of hemolysis in malaria-infected patients","volume":"17","author":"Avalos S","year":"2018","unstructured":"Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, Galo S, Pinto A, Mejia A, Fontecha G. G6PD deficiency, primaquine treatment, and risk of hemolysis in malaria-infected patients. Malar J. 2018;17:1\u201311.","journal-title":"Malar J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","article-title":"Anemia and malaria","volume":"17","author":"White NJ","year":"2018","unstructured":"White NJ. Anemia and malaria. Malar J. 2018;17:371.","journal-title":"Malar J"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12936-021-03921-w","article-title":"Safety monitoring experience of single-low dose primaquine coadministered with artemether-lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania","volume":"20","author":"Mosha D","year":"2021","unstructured":"Mosha D, Kakolwa MA, Mahende MK, Masanja H, Abdulla S, Drakeley C, Gosling R, Wamoyi J. Safety monitoring experience of single-low dose primaquine coadministered with artemether-lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania. Malar J. 2021;20:392.","journal-title":"Malar J"},{"key":"ref52","first-page":"2268","article-title":"What causes malaria anemia?","volume":"139","author":"White NJ","year":"2022","unstructured":"White NJ. What causes malaria anemia? Blood J Am Soc Hematol. 2022;139:2268\u20139.","journal-title":"Blood J Am Soc Hematol"},{"key":"ref53","author":"Barcellini W","year":"2015","unstructured":"Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease markers 2015, 2015."},{"key":"ref54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s13071-021-05034-4","article-title":"Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa","volume":"14","author":"Beek SW","year":"2021","unstructured":"van Beek SW, Svensson EM, Tiono AB, Okebe J, D'Alessandro U, Gon\u00e7alves BP, Bousema T, Drakeley C, Ter Heine R. Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa. Parasit Vectors. 2021;14:524.","journal-title":"Parasit Vectors"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12936-023-04493-7","article-title":"Association of G6PD status and hemolytic anemia in patients receiving anti-malarial agents: a systematic review and meta-analysis","volume":"22","author":"Nelwan EJ","year":"2023","unstructured":"Nelwan EJ, Shakinah S, Pasaribu A. Association of G6PD status and hemolytic anemia in patients receiving anti-malarial agents: a systematic review and meta-analysis. Malar J. 2023;22:77.","journal-title":"Malar J"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12936-017-1989-3","article-title":"Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies","volume":"16","author":"Uthman OA","year":"2017","unstructured":"Uthman OA, Graves PM, Saunders R, Gelband H, Richardson M, Garner P. Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malar J. 2017;16:346.","journal-title":"Malar J"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4095915\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4095915\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:40:13Z","timestamp":1710528013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4095915\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":56,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4095915\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,3,15]]},"subtype":"preprint"}}